TRP_1170x120_3-8-19

GPhA

New name for Generic Pharmaceutical Association

New name for Generic Pharmaceutical Association

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly

Savings from generic drugs edge up

Savings from generic drugs edge up

WASHINGTON — Annual health care savings from generic prescription drugs rose nearly 10% last year to $227 billion, according to the Generic Pharmaceutical Association (GPhA). GPhA’s 2016 Generic Drug Savings and Access in the United States report, released Wednesday, tallied the 10-year national savings for generics at $1.46 trillion, representing a gain of 328% from

FDA pushes back generic drug labeling rule

FDA pushes back generic drug labeling rule

WASHINGTON — The Food and Drug Administration is again postponing the release of a final rule that would change generic drug labeling requirements. In a Federal Register notice this week, the FDA indicated that it aims to implement the final rule in April 2017, though many industry stakeholders had expected the agency to do so

GPhA tabs Mylan’s Bresch to chair board

GPhA tabs Mylan’s Bresch to chair board

ORLANDO, Fla. — The Generic Pharmaceutical Association (GPhA) has elected Heather Bresch, chief executive officer of Mylan, to chair its board of directors this year. GPhA, which announced the move at its 2016 Annual Meeting here, also named other officers to its 2016 board and executive committee: Jeff Watson, president of global generics at Apotex,

GPhA tallies savings from generic drug use

GPhA tallies savings from generic drug use

WASHINGTON — The U.S. health care system saved a record $254 billion last year through the use of lower-cost generic drugs, the Generic Pharmaceutical Association (GPhA) reports. Over the past decade, covering 2005 to 2014, the savings yielded by the use of generics over their more expensive brand-name counterparts totals $1.68 trillion, according to the

GPhA council works to promote biosimilars

GPhA council works to promote biosimilars

Biosimilars offer tremendous promise for millions of Americans suffering from cancer, rheumatoid arthritis or other diseases, offering lower-cost and highly effective alternatives to costly reference product drugs, also known as biologics. Biosimilars have been approved and prescribed effectively for close to a decade in nations across Europe and in Australia, offering patients increased access to

FDA proposes suffix for biosimilar product names

FDA proposes suffix for biosimilar product names

WASHINGTON — Early feedback on the Food and Drug Administration’s proposal on naming conventions for biosimilars shows a mixed response. Late late week, the FDA published draft guidance recommending that reference biologic products and biosimilars have nonproprietary names that share a core drug substance name and an FDA-designated suffix unique for each product. For interchangeable

GPhA tabs Davis as new CEO

GPhA tabs Davis as new CEO

WASHINGTON — Chester “Chip” Davis has been named president and chief executive officer of the Generic Pharmaceutical Association (GPhA), taking over from Ralph Neas, who is stepping down. GPhA said Wednesday that Davis, previously executive vice president for advocacy and member relations at Pharmaceutical Research and Manufacturers of America (PhRMA), is slated to start in

State biosimilars legislation hailed by GPhA

WASHINGTON — The Generic Pharmaceutical Association (GPhA) and its recently formed Biosimilars Council have praised the enactment of new legislation in five states to allow automatic substitution for Food and Drug Administration-approved interchangeable biologic products. Bills in Colorado (SB 71), Georgia (SB 51), Tennessee (SB 984), Utah (HB 279) and Washington (SB 5935) reflect core

Neas to leave GPhA in the autumn

WASHINGTON — Ralph Neas, president and chief executive officer of the Generic Pharmaceutical Association, has announced he will step down from his position in the fall. Neas has led GPhA since September 2011. During his remaining tenure, he will continue to serve as CEO until a successor is named and will work to ensure a

Senate report calls for higher generics usage

WASHINGTON — Providing incentives to prescription drug plan sponsors that increase generic drug use is among recommendations that the Senate Special Committee on Aging unveiled last month in a bipartisan report that focuses on ways to increase the utilization of generics within the Medicare Part D program. The panel also heard about industry issues beyond